Archive for February 2nd, 2012

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the Endocrinologic and Metabolic Drugs Advisory Committee expects to discuss the lorcaserin New Drug Application (NDA) resubmission for obesity during 2Q 2012. The PDUFA target date is June 27, 2012. Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) said that it intends to file a Marketing Authorization Application (MAA) in the EU […]

Latest Articles

Dear readers of BioPharmCatalyst, Thank you to all readers who have followed and supported BioPharmCatalyst over the past five years. Yes, that’s correct, BioPharmCatalyst celebrated it’s 5th anniversary earlier this week. BPC is run independently and a change in working circumstances has meant that updating the website has become quite time consuming to maintain over the past […]

Latest updates to the Company Pipeline Database for May 18 and 19, 2015. Refer to the FDA Calendar for upcoming catalysts: In addition, over 100 updates were made over the weekend as companies continued with their reporting season. You can find the updates from last week by clicking the “updated” column on the far right of the Company Pipeline Database. […]